Omega-3 polyunsaturated fatty acids in critically ill patients with acute respiratory distress syndrome: A systematic review and meta-analysis
- PMID: 30703574
- PMCID: PMC10019281
- DOI: 10.1016/j.nut.2018.10.026
Omega-3 polyunsaturated fatty acids in critically ill patients with acute respiratory distress syndrome: A systematic review and meta-analysis
Abstract
Objective: Acute respiratory distress syndrome (ARDS) is characterized by an acute inflammatory response in the lung parenchyma leading to severe hypoxemia. Because of its anti-inflammatory and immunomodulatory properties, omega-3 polyunsaturated fatty acids (ω-3 PUFA) have been administered to ARDS patients, mostly by the enteral route, as immune-enhancing diets with eicosapentaenoic acid, γ-linolenic acid, and antioxidants. However, clinical benefits of ω-3 PUFAs in ARDS patients remain unclear because clinical trials have found conflicting results. Considering the most recent randomized controlled trials (RCTs) and recent change in administration strategies, the aim of this updated systematic review and meta-analysis was to evaluate clinical benefits of ω-3 PUFA administration on gas exchange and clinical outcomes in ARDS patients.
Methods: We searched for RCTs conducted in intensive care unit (ICU) patients with ARDS comparing the administration of ω-3 PUFAs to placebo. The outcomes assessed were PaO2-to-FiO2 ratio evaluated early (3-4 d) and later (7-8 d), mortality, ICU and hospital length of stay (LOS), length of mechanical ventilation (MV), and infectious complications. Two independent reviewers assessed eligibility, risk of bias, and abstracted data. Data were pooled using a random effect model to estimate the relative risk or weighted mean difference (WMD).
Results: Twelve RCTs (n = 1280 patients) met our inclusion criteria. Omega-3 PUFAs administration was associated with a significant improvement in early PaO2-to-FiO2 ratio (WMD = 49.33; 95% confidence interval [CI] 20.88-77.78; P = 0.0007; I2 = 69%), which persisted at days 7 to 8 (WMD = 27.87; 95% CI 0.75-54.99; P = 0.04; I2 = 57%). There was a trend in those receiving ω-3 PUFA toward reduced ICU LOS (P = 0.08) and duration of MV (P = 0.06), whereas mortality, hospital LOS, and infectious complications remained unchanged. Continuous enteral infusion was associated with reduced mortality (P = 0.02), whereas analysis restricted to enteral administration either with or without bolus found improved early PaO2 and FiO2 (P = 0.001) and MV duration (P = 0.03). Trials at higher risk of bias had a significant reduction in mortality (P = 0.04), and improvement in late PaO2-to-FiO2 ratio (P = 0.003).
Conclusions: In critically ill patients with ARDS, ω-3 PUFAs in enteral immunomodulatory diets may be associated with an improvement in early and late PaO2-to-FiO2 ratio, and statistical trends exist for an improved ICU LOS and MV duration. Considering these results, administering ω-3 PUFAs appears a reasonable strategy in ARDS.
Keywords: Acute respiratory distress syndrome; Fish oil; Gas exchange; Omega-3.
Copyright © 2018 Elsevier Inc. All rights reserved.
Figures







Comment in
-
Comment on "Omega-3 polyunsaturated fatty acids in critically ill patients with acute respiratory distress syndrome: a systematic review and meta-analysis".Nutrition. 2021 Oct;90:111421. doi: 10.1016/j.nut.2021.111421. Epub 2021 Jul 21. Nutrition. 2021. PMID: 34400014 Free PMC article. No abstract available.
-
Authors' response to comment on "Omega-3 polyunsaturated fatty acids in critically ill patients with acute respiratory distress syndrome: a systematic review and meta-analysis".Nutrition. 2021 Oct;90:111432. doi: 10.1016/j.nut.2021.111432. Epub 2021 Jul 25. Nutrition. 2021. PMID: 34456087 No abstract available.
Similar articles
-
Immunonutrition for acute respiratory distress syndrome (ARDS) in adults.Cochrane Database Syst Rev. 2019 Jan 24;1(1):CD012041. doi: 10.1002/14651858.CD012041.pub2. Cochrane Database Syst Rev. 2019. PMID: 30677127 Free PMC article.
-
Current evidence on ω-3 fatty acids in enteral nutrition in the critically ill: A systematic review and meta-analysis.Nutrition. 2019 Mar;59:56-68. doi: 10.1016/j.nut.2018.07.013. Epub 2018 Jul 31. Nutrition. 2019. PMID: 30419501
-
Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group.Crit Care Med. 1999 Aug;27(8):1409-20. doi: 10.1097/00003246-199908000-00001. Crit Care Med. 1999. PMID: 10470743 Clinical Trial.
-
Effect of enteral immunomodulatory nutrition formula on mortality and critical care parameters in critically ill patients: A systematic review with meta-analysis.Nurs Crit Care. 2022 Nov;27(6):838-848. doi: 10.1111/nicc.12687. Epub 2021 Jul 29. Nurs Crit Care. 2022. PMID: 34323346
-
Nutritional immunomodulation in critically ill children with acute lung injury: feasibility and impact on circulating biomarkers.Pediatr Crit Care Med. 2013 Jan;14(1):e45-56. doi: 10.1097/PCC.0b013e31827124f3. Pediatr Crit Care Med. 2013. PMID: 23295853 Clinical Trial.
Cited by
-
Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) for Immunomodulation in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS).J Clin Med. 2022 Dec 30;12(1):304. doi: 10.3390/jcm12010304. J Clin Med. 2022. PMID: 36615103 Free PMC article. Review.
-
A case-control study on the diagnostic role of Omega-3 fatty acid levels in erythrocyte membranes of critically ill patients.Sci Rep. 2025 Jul 14;15(1):25390. doi: 10.1038/s41598-025-09391-3. Sci Rep. 2025. PMID: 40659684 Free PMC article.
-
Plasma Oxylipins and Their Precursors Are Strongly Associated with COVID-19 Severity and with Immune Response Markers.Metabolites. 2022 Jul 4;12(7):619. doi: 10.3390/metabo12070619. Metabolites. 2022. PMID: 35888743 Free PMC article.
-
The Role of Innate Immunity and Bioactive Lipid Mediators in COVID-19 and Influenza.Front Physiol. 2021 Jul 22;12:688946. doi: 10.3389/fphys.2021.688946. eCollection 2021. Front Physiol. 2021. PMID: 34366882 Free PMC article. Review.
-
Nutritional approach for increasing public health during pandemic of COVID-19: A comprehensive review of antiviral nutrients and nutraceuticals.Health Promot Perspect. 2021 May 19;11(2):119-136. doi: 10.34172/hpp.2021.17. eCollection 2021. Health Promot Perspect. 2021. PMID: 34195036 Free PMC article. Review.
References
-
- Force A.D.T., Ranieri V.M., Rubenfeld G.D., Thompson B.T., Ferguson N.D., Caldwell E., et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526–2533. - PubMed
-
- Calder P.C. Polyunsaturated fatty acids, inflammation, and immunity. Lipids. 2001;36:1007–1024. - PubMed
-
- Singer P., Shapiro H., Theilla M., Anbar R., Singer J., Cohen J. Anti-inflammatory properties of ω-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med. 2008;34:1580–1592. - PubMed
-
- Pontes-Arruda A., Aragao A.M., Albuquerque J.D. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med. 2006;34:2325–2333. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous